Endpoint
Asymmetric dimethylarginine (ADMA) concentration
CAT:outcome/admareported in umol/L1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| methylcob(III)alamin | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
1 finding
methylcob(III)alamin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The percentage of decrease in ADMA levels was greater in the methylcobalamin than folate group (25.4% +/- 10.2% vs 13.2% +/- 11.2%; P < 0.001).”
Quoted verbatim from Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.. - Study
- RCT
- Duration
- 3 weeks
- Dose
- 500 mcg intravenous methylcobalamin after each hemodialysis treatment, 3 times weekly, plus folate 15 mg/d
- Population
- Maintenance hemodialysis patients; oral folate 15 mg/d given to both arms as background, methylcobalamin added in one arm; 3 weeks, open-label
Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.2010PMID:20430500Permalink
How it is measured
Circulating asymmetric dimethylarginine in plasma or serum by HPLC, LC-MS/MS or ELISA. Assay platform recorded with each finding — ELISA and mass-spectrometry values are not interchangeable and differ systematically in absolute concentration.
Sources cited
1 paper
- Subject
- asymmetric dimethylarginine (adma) concentration
- Findings
- 1
- Papers
- 1